← Back to all trials
Recruiting
NCT05735782
Clinical and Biological Characterization of Post COVID-19 Syndrome
Conditions: Long COVID
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: 1
Enrollment: 75
Sponsor: Arturo Jauretche National University
Location: Argentina
Summary
The goal of this observational study is to describe the symptoms that persist for more than 12 weeks after the acute episode in participants who had COVID-19, and compare the functional, socioeconomic and occupational effects with a post-COVID-19 control group without persistent symptoms after the COVID-19 acute event.The main questions it aims to answer are:What are the characteristics of symptoms that persist for more than 12 weeks in participants who have had COVID19 in the last year?What are the health-related quality of life and psychosocial effects in participants with persistent symptoms of COVID-19, compared to a post-COVID-19 control group without persistent symptoms after the acute episode of COVID-19?
Eligibility Criteria
Two groups of cases and one group of controls will be included.
A group of cases with persistent respiratory and/or cardiovascular symptoms (cardiorespiratory cases), and another group with persistent non-cardiorespiratory symptoms.
For participation in the study, people who meet the following inclusion criteria and none of the exclusion criteria will be considered.Inclusion Criteria:Age equal to or greater than 18 years;Documented SARS-CoV-2 infection by PCR or antigen test;Ability to understand the objectives of the study;Acceptance to participate in the study and willingness to sign the informed consent.Permanent residence in Buenos Aires Metropolitan Area.Exclusion Criteria:Women who report being pregnant, who are in the puerperium or lactation period at the time of the evaluation.People with known chronic debilitating conditions, defined as:i. heart failure, ii.
symptomatic Coronary Heart Disease, iii.
Diagnosis of cancer in the last 5 years iv.
symptomatic anemia, v. chronic obstructive pulmonary disease or greater than moderate asthma, vi.
heart valve disease more than mild, vii.
cognitive impairment prior to the diagnosis of COVID-19, viii.
diagnosis of schizophrenia or depression, ix.
any other condition that, at the discretion of the treating professional or the research team, may explain or justify the aforementioned symptoms.Participants who are undergoing an acute pathology or who have undergone it in the last 4 weeks.
In this case, they may be contacted again, after the period of time considered acceptable by the treating professional or the research team to invite them to participate.
Source: ClinicalTrials.gov (NCT05735782). StuddyBuddy aggregates publicly available trial information.